BPMC Blueprint Medicines
- 89.540
- +1.190+1.35%
- 89.540
- 0.0000.00%
Blueprint Medicines News
Blueprint Medicines | 4: Statement of changes in beneficial ownership of securities-Officer Rossi Christina
Blueprint Medicines | 4: Statement of changes in beneficial ownership of securities-Director Albers Jeffrey W.
Blueprint Medicines | 144: Notice of proposed sale of securities pursuant to Rule 144
Blueprint Medicines | 8-K: Current report
Blueprint Medicines | 4: Statement of changes in beneficial ownership of securities-Officer Hurley Ariel
Blueprint Medicines | 144: Notice of proposed sale of securities pursuant to Rule 144
Blueprint Medicines | 4: Statement of changes in beneficial ownership of securities-Officer Haviland Kate
Blueprint Medicines | 4: Statement of changes in beneficial ownership of securities-Officer Rossi Christina
Blueprint Medicines | 144: Notice of proposed sale of securities pursuant to Rule 144
Blueprint Medicines | 144: Notice of proposed sale of securities pursuant to Rule 144
Blueprint Medicines | 4: Statement of changes in beneficial ownership of securities-Director COATS LONNEL
Blueprint Medicines | 144: Notice of proposed sale of securities pursuant to Rule 144
Blueprint Medicines | 144: Notice of proposed sale of securities pursuant to Rule 144
Blueprint Medicines | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-T. ROWE PRICE ASSOCIATES, INC.(8.5%)
Blueprint Medicines | 4: Statement of changes in beneficial ownership of securities-Director Albers Jeffrey W.
Blueprint Medicines | 144/A: Others
Blueprint Medicines | 144: Notice of proposed sale of securities pursuant to Rule 144
Blueprint Medicines | 10-Q: Q3 2024 Earnings Report
Blueprint Medicines | 8-K: Blueprint Medicines Reports Third Quarter 2024 Results and Raises AYVAKIT® / AYVAKYT ® (avapritinib) Full Year Revenue Guidance
Blueprint Medicines | 4: Statement of changes in beneficial ownership of securities-Officer Namouni Fouad
No Data
